针对线粒体的循环金属化和支架 抗瘤药物
Jiali Jiang1, Ziyan Xue1, Qiwei Lu2
1Jiangsu Collaborative Innovation Center of Biomedical Functional Materials, Nanjing Drum Tower Hospital, College of Chemistry and Materials Science, Nanjing Normal University, Nanjing, 210023, China. zhisu@njnu.edu.cn.
Dalton transactions (Cambridge, England : 2003)
|November 10, 2025
概括
循环金属化 ((III) 复合物显示出作为针对线粒体的新型抗癌剂的前景. 这些化合物具有可调节的特性,并有可能用于先进的化疗,免疫疗法和光动力疗法.
科学领域:
- 药用化学 医学化学
- 纳米技术纳米技术
- 生物化学 生物化学
背景情况:
- 传统的金属药物,如西斯,面临着挑战,包括耐药性和毒性.
- 线粒体对于瘤细胞的生存至关重要,使他们成为癌症治疗的关键目标.
- 循环金属化 (III) 复合物具有独特的光物理特性和有针对性的生物活性.
研究的目的:
- 系统地审查最近在线粒体向抗瘤循环金属化支架的进展.
- 突出分子设计策略及其在癌症治疗中的实施.
- 探索这些复合物的化学疗法,免疫疗法和光动力疗法的潜力.
主要方法:
- 汇编和分析最近关于 (III) 复合物的研究成果.
- 专注于用于线粒体向的分子设计原则.
- 治疗应用的审查,包括化疗,免疫疗法和光动力疗法.
主要成果:
- 线粒体向的 (III) 复合物表现出可调节的配体亲和力和低暗毒性.
- 这些复合体显示出对刺激反应性癌症治疗的潜力.
- 在各种治疗方式中利用,包括化疗,免疫疗法和光动力疗法.
结论:
- 针对线粒体的环金属化 (Cyclometalate Iridium) 复合物代表了下一代有希望的抗癌药物.
- 进一步研究药物输送,优化和临床翻译是有必要的.
- 这些支架为创新的癌症治疗策略提供了巨大的潜力.
相关概念视频
Electron Transport Chain: Complex I and II
18.4K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
18.4K
Drugs that Destabilize Microtubules
3.6K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
3.6K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Drugs that Stabilize Microtubules
2.6K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.6K
M-Cdk Drives Transition Into Mitosis
6.2K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.2K
Translocation of Proteins into the Mitochondria
11.9K
Mitochondrial precursors are translocated to the internal subcompartments via independent mechanisms involving distinct protein machineries called translocases.
Sorting of outer membrane proteins:
Mitochondrial outer membrane proteins are of two types: the transmembrane, beta-barrel porins, and the membrane-anchored, alpha-helical proteins. Beta-barrel porin precursors are translocated by the TOM complex and inserted into the outer mitochondrial membrane by the SAM complex. In contrast,...
Sorting of outer membrane proteins:
Mitochondrial outer membrane proteins are of two types: the transmembrane, beta-barrel porins, and the membrane-anchored, alpha-helical proteins. Beta-barrel porin precursors are translocated by the TOM complex and inserted into the outer mitochondrial membrane by the SAM complex. In contrast,...
11.9K


